Wuhongqian

1、Educational Experience

(1) 2014/09-2017/06, China pharmaceutical university, PhD

(2) 2011/09-2014/06, China pharmaceutical university, Master

(3) 2007/09-2011/06, China pharmaceutical university, Bachelor 

2、Working Experience

(1) 2017/06 -Now, Department of Pharmacology, School of Pharmacy,China pharmaceutical university

1.Wu, H.;  Li, Y.;  Shi, G.;  Du, S.;  Wang, X.;  Ye, W.;  Zhang, Z.;  Chu, Y.;  Ma, S.;  Wang, D.;  Li, Y.;  Chen, Z.;  Birnbaumer, L.;  Wang, Z.^*; Yang, Y.^*, Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology 2022. doi.org/10.1002/hep.32316. Online ahead of print.  (IF:17.292)

2.Li, Y.;  Chu, Y.;  Shi, G.;  Wang, X.;  Ye, W.;  Shan, C.;  Wang, D.;  Zhang, D.;  He, W.;  Jiang, J.;  Ma, S.;  Han, Y.;  Zhao, Z.;  Du, S.;  Chen, Z.;  Li, Z.;  Yang, Y.;  Wang, C.^*;  Xu, X.^*; Wu, H.^*, A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. Acta Pharmaceutica Sinica B 2022. Online ahead of print.  (IF:14.903)

3.Shi, G.;  Zhang, Z.;  Ma, S.;  Li, Y.;  Du, S.;  Chu, Y.;  Li, Y.;  Tang, X.;  Yang, Y.;  Chen, Z.^*;  Wang, Z.^*; Wu, H.^*, Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice. Biochem Pharmacol 2021, 192, 114728. (IF: 5.858)

4.Wang, X.;  Mao, J.;  Zhou, T.;  Chen, X.;  Tu, H.;  Ma, J.;  Li, Y.;  Ding, Y.;  Yang, Y.^*;  Wu, H.^*; Tang, X.^*, Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics 2021, 11 (1), 209-221. (IF: 11.556)

5.Zheng, S.;  Ni, J.;  Li, Y.;  Lu, M.;  Yao, Y.;  Guo, H.;  Jiao, M.;  Jin, T.;  Zhang, H.;  Yuan, A.;  Wang, Z.;  Yang, Y.;  Chen, Z.^*;  Wu, H.^*; Hu, W.^*, 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop. Pharmacol Res 2021, 169, 105685. (IF: 7.658)

6.Wu, H.;  Ren, J.;  Zhao, L.;  Li, Z.;  Ye, W.;  Yang, Y.;  Wang, J.^*; Bian, J.^*, Identification of novel androgen receptor degrading agents to treat advanced prostate cancer. Eur J Med Chem 2021, 217, 113376. (IF: 6.514)

7.Wu, H.;  You, L.;  Li, Y.;  Zhao, Z.;  Shi, G.;  Chen, Z.;  Wang, Z.;  Li, X.;  Du, S.;  Ye, W.;  Gao, X.;  Duan, J.;  Cheng, Y.;  Tao, W.;  Bian, J.;  Zhou, J. R.;  Zhu, Q.; Yang, Y., Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Res 2020, 80 (13), 2927-2939. (IF: 12.701)

8.Wu, H.;  Zhang, L.;  Gao, X.;  Zhang, X.;  Duan, J.;  You, L.;  Cheng, Y.;  Bian, J.;  Zhu, Q.; Yang, Y. ^*, Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer. Cancer Lett 2017, 385, 108-116. (IF: 6.491)

Aim to identify drug targets and drug discovery for the treatment and management of Cancer, Liver diseases and Inflammation.

(1) National Natural Science Foundation of China (No. 82273968), Mechanism of hepatic IRF8-mediated tumor associated macrophages polarization by suppressing tumor methionine metabolism, 2023/01-2026/12, RMB560,000, in progress.

(2) Fundamental Research Funds for the Central Universities (NO.2632022ZD13), Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD1 therapy, 2022/01-2023/12, RMB200,000, in progress.

(3) National Natural Science Foundation of China (No. 81903656), Effect and mechanism of a novel AR antagonist candidate compound LLU-206 in PCa by interrupting in the formation of AR/ARv7 complex, 2020/01-2022/12, RMB210,000, Completed.

(4) Natural Science Foundation of Jiangsu Province (No. BK20180560), The mechanism for IRF8-AR axis in the development and Enzalutamide sensitivity of hepatocellular carcinoma, 2018/07-2021/06, RMB200,000, Completed.

China Postdoctoral Science Foundation (No. 2018M632430), The mechanism for IRF8-AR axis in the development and Enzalutamide sensitivity of hepatocellular carcinoma, 2019/01-2020/12, RMB50,000, Completed.